Nashville-based Healthcare Consulting Group, FKP Advisors, joins the Board of Directors of Healthcare Integrated Technologies Inc.
Knoxville, TN, April 22, 2025 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies Inc. (OTC PINK: HITC), a global leader in AI-driven safety and monitoring solutions, is proud to announce the appointment of FKP Advisors LLC, a Nashville-based healthcare consulting group, to its Board of Directors. FKP Advisors LLC board seat will be on a rotational basis with its founding partners: Larry Kloess III serving in the first year, followed by Jim Fitzgerald in the second year, and Ben Pope in the third Year.
Mr. Kloess is a healthcare executive with over 40 years of leadership experience in hospital and physician group management. Mr. Fitzgerald served as the founding President and CEO of HealthTrust Purchasing Group, where he oversaw its initial formation in 1999. Prior to founding HealthTrust, he served as President of HCA's supply chain services, as well as several other leadership roles within HCA. Mr. Pope has over 35 years' experience in the medical and healthcare field.
'We are thrilled to welcome the founding partners of FKP Advisors to our Board of Directors,' said Scott Boruff, CEO of Healthcare Integrated Technologies. 'Their deep experience in healthcare and medical and their respective perspectives, will be invaluable as we continue to scale our platform, expand our market presence, and advance our mission ofrevolutionizing school, healthcare, transportation and commercial building monitoring and security, utilizing our proprietary AI technology.'
'We are honored to join the board of Healthcare Integrated Technologies, at such a pivotal time in its journey, said Mr. Kloess. 'HITC is at the forefront of AI-driven innovation, and we look forward to supporting its mission and long-term vision, as it continues to drive meaningful impact in helping save lives in the various industries in which it serves.'
As HITC continues to innovate and grow, the appointment of FKP Advisors underscores the Company's commitment to securing top-tier leadership, to advance its vision and create a lasting impact on the ambient AI safety space.
About Healthcare Integrated Technologies Inc.
Healthcare Integrated Technologies Inc. is a publicly traded, fully reporting audited company specializing in ambient AI technology solutions, dedicated to enhancing safety and security across various sectors, including healthcare, education, transportation, manufacturing, incarceration, and commercial industries. The Company's mission is to help save lives worldwide by developing advanced AI technologies designed to enhance situational awareness and mitigate risks in critical environments. The Company is currently marketing five products and solutions, including its initial product, SafeSpace® Fall Monitoring, which utilizes advanced AI monitoring tools to enhance resident safety in senior living, reduce the risk of injuries, and improve overall care efficiency. Additionally, the Company has expanded its services and offerings beyond senior living facilities, into schools and transportation where it has recently launched several innovative solutions.
For more information, visit www.gethitc.com or contact HITC's media team at [email protected].
Media Contact:
Justin Freishtat
(410) 458-8780
Healthcare Integrated Technologies Inc.
Email: [email protected]
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are subject to uncertainty and may not come to fruition. Readers are cautioned not to place undue reliance on any forward-looking statement including statements that list numbers and dates.
###
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Air Force spends millions on relaxation cubes that may prove worth it
At dozens of bases across the Air Force, troops are undertaking tried-and-true relaxation techniques — biofeedback, meditation — in shiny mirrored cubes that can project light patterns and even galaxies. The experience, as one researcher put it, is more like a 'Disney ride' than a studio or clinical office. This is Lumena Mindgym, a flashy new curriculum-based therapeutic tool that's taking the Air Force by storm. More than two dozens Mindgyms have been installed at base fitness centers and support facilities for about $100,000 apiece; Mindgym just marked its first installations outside the continental United States, in Kuwait and Turkey, earlier this year. As the number of Mindgym advocates across the Air Force grows, other services are also entering talks to purchase the technology. It's a lot of flash and glitz to deliver relaxation to stressed-out service members. But the number of passionate advocates for Mindgym in the military is growing, and some argue the attention it's getting from troops who might otherwise avoid meditation and de-stressing techniques might make it worth every penny. The technology itself was created by an entrepreneur with a finance background, rather than a scientist; company executives make clear they are not the clinical experts. 'We don't have anybody in-house that's a neuroscientist or Ph.D.,' Brandon Murphy, head of growth for Lumena, told Military Times in an interview, adding that they did maintain an advisory board of doctors and researchers. Nor was Mindgym designed with the military specifically in mind. Founders were shopping the technology at a Colorado-based sporting tradeshow in 2019, Murphy said, when they encountered Adam Strang, Biotechnology Product Line Lead at the Air Force Research Laboratory. Strang was intrigued by the tech and connected the team with veteran Air Force pilot and human performance expert Jannell MacAulay, who'd become a vocal advocate for Mindgym and help develop the curriculum to be used by airmen. 'It's like a flight simulator for your mind,' MacAulay posted on Facebook in April during a visit to one of the Air Force's facilities. By 2022, a seed fund grant had enabled the installation of the first Mindgym at Hill Air Force Base, Utah, complete with a clinically validated curriculum and wearable components that measured brain activity and heart rate. The first users were explosive ordnance disposal technicians from Hill's 775th Civil Engineering Squadron. And that initial group of 55 airmen gave Mindgym its best evidence for effectiveness. Over 219 20-minute training sessions, according to Lumena Labs, the group self-reported an average 30% improvement in mood. The biodata receptors documented a 16.2% reduction in stress indicators, while 61% of users said their stress management capabilities improved. Sleep quality also improved for 15% of users. 'Many in the group reported stronger focus during the Weighted Airmen Performance Systems (WAPS) testing — the program that determines promotions for Staff Sergeant (E-5) and Technical Sergeant (E-6),' Lumena stated in study analysis. 'They also cited decreased incidents of road rage and across-the-board improvements in their marital relations, gym workouts, and even their golf scores.' While follow-up studies have not been conducted, the feedback appears to demonstrate how even a small amount of therapeutic attention to the brain and the mental resilience of service members under stress can make a significant difference. Strang, at the Air Force Research Lab, told Military Times in an interview that Mindgym compared favorably to the sensory deprivation float tanks popular for promoting relaxation and stress reduction. 'Float tanks are messy and maintenance is challenging,' Strang said, adding that it was never clear to him if the atmosphere of the tank or the opportunity to take a nap in it made the most difference to his mental state. 'I hopped into Mindgym, and it didn't feel like a waterless float tank to me at all,' he said. 'It felt like a psychedelic experience.' AFRL has plans to study the efficacy of Mindgym in comparison with other mindfulness and relaxation technologies, though those are predicated on future funding awards. Strang emphasized that Mindgym is not a panacea for mental health or resilience but said boosting cognition and reducing stress, particularly in a 'next frontier' warfare environment where troops are joining a real fight from their desks as drone pilots or Space Force satellite operators, was worth the dedicated investment. 'They're $100,000 cubes, I think, the last time I checked,' Strang said. 'Let's say they facilitate relaxation and recovery across 100 people by 10%; what's the operational impact of that? I don't know. But what happens if one person who is flying an F-35 sits in that cockpit and, because of these interventions, prevents a mishap of a $60 million aircraft? Would that be worth it? Probably.' As the Air Force continues to install Mindgyms, the company has recently had more conversations with Navy officials, even demonstrating the Mindgym at the Sea Air Space naval trade show earlier this year. Murphy said he saw value for the technology particularly in the submarine community, where stress and operational tempo were high. There are now 32 different sessions a service member can select in Mindgym; a grant last year enabled the recent development and deployment of a stroboscopic light therapy protocol that is supposed to promote higher theta brain wave state, enabling reduced stress in high-intensity situations. 'I'd honestly love to have [a Mindgym] on every military base on the globe,' Murphy said, 'so that there's not a service member that doesn't have access to something like this.'
Yahoo
43 minutes ago
- Yahoo
Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing
NEWPORT NEWS, Va., June 9, 2025 /PRNewswire/ -- Dilon Technologies®, a global leader in medical devices for biosurgery and breast cancer treatment and diagnosis, today announced a $9 million growth capital investment from JGB Management Inc. The investment will support Dilon's continued double-digit revenue growth and operational scaling. Dilon Technologies has built a robust presence in surgical settings with a portfolio of products that improve clinical outcomes. "We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide," said George Makhoul, CEO of Dilon Technologies. "This funding empowers us to continue delivering best-in-class innovations that improve patient care." HEMOBLAST Bellows® is a groundbreaking advanced hemostatic agent used in a wide range of surgeries—including cardiac, general, and orthopedic procedures. It remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST® Bellows continues to redefine standards in surgical hemostasis. Another key product, MarginProbe® an in-surgery, real-time breast cancer margin assessment device. It enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. Clinical studies show MarginProbe® reduces re-excision rates by 25% to 80%. A 2025 study published in The American Surgeon Journal highlighted a 42% reduction in re-excision for patients with DCIS. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end. Dilon's Navigator™ Gamma Probe product line, a market-leading tool for radio-guided lymphatic mapping and tumor localization, continues to perform strongly worldwide. A new, enhanced version is expected to launch by late 2025. "We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide," said Brett Cohen, CEO of JGB Management Inc. For more information, visit About Dilon Technologies® Technologies® Inc. is a commercial-stage medical device company that develops, manufactures, and markets innovative technologies used in hemostasis, cancer detection and assessment, and airway management. Dilon's growing surgical portfolio includes: HEMOBLAST Bellows®: The only FDA-approved powder-form hemostatic agent for minimal, mild, and moderate bleeding. MarginProbe®: A groundbreaking real-time margin assessment tool for breast cancer surgery. Navigator™ System: A leading surgical gamma probe for tumor localization and lymphatic mapping. TrueView 100 Pro: A surgical specimen analyzer for intraoperative use. CoPilot VL+®: A compact, portable video laryngoscope for airway visualization. About JGB Management Inc. JGB Management Inc., founded by Brett Cohen in 2005, is an alternative asset management firm focused on investing in niche credit-oriented situations. JGB specializes in privately negotiated investments. The firm is based in Westport CT. View original content to download multimedia: SOURCE Dilon Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
Poster Presentation Reviews the Hemopurifier® Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025 ( Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective. Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID. EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation. Aethlon Medical's Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose. The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered from COVID-19 in order to examine whether individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively. Presentation details and times are as follows: Title: Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier® Authors: Miguel Pesqueira1, Rosalia de Necochea Campion1, Thomas Dalhuisen2, Emily A. Fehrman2, Jeffrey N. Martin2, Timothy J. Henrich2, Steven G. Deeks2, Michael J. Peluso2, Steven P. LaRosa1 Aethlon Medical Inc., San Diego, CA, USA University of California, San Francisco, San Francisco, CA, USA Presenter: Steven P. LaRosa, M.D, Chief Medical Officer, Aethlon Medical, Number: 2001Date and Time: August 12, 2025, 1930, MDT. This poster will be available following the meeting on the Aethlon Medical, Inc. corporate website at About Aethlon and the Hemopurifier® Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation, and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@ Investor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@ View original content: SOURCE Aethlon Medical, Inc. Sign in to access your portfolio
